Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors

Award Number: UH2CA240688
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/02/2019
PERIOD OF PERFORMANCE END DATE: 04/30/2022

Group Awards By:

View Award Description

Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors - PROJECT SUMMARY Germ cell tumors (GCT) are the most common solid tumor of adolescents and young adults. After resection of the primary tumor, many patients do not have evidence of disease elsewhere and are categorized as “clinical stage I (CSI) patients.” The current standard of care for CSI patients is “active surveillance” with serum tumor markers and imaging. However, between 20-50% of these patients will relapse. Moreover, the serum tumor markers that are currently available, AFP and HCG, are present in only 50% of the cases. A biomarker that could predict the likelihood of relapse in the immediate post-op period and detect relapse accurately in all patients on surveillance would rationalize medical decision-making, allowing for immediate initiation of chemotherapy in those at high likelihood of relapse and earlier detection of relapse of those on surveillance. An accurate serum biomarker would also obviate the need for most of the serial surveillance CT scans, reducing radiation exposure and health care costs. Our group has identified a panel of 4 serum miRNAs (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p) that, in over 1500 cases analyzed retrospectively to date, appear to be universally elevated regardless of age, gender, site of primary, or the principal histology of the GCT. We have developed a rigorous pipeline to quantify the levels of these 4 miRNAs using quantitative reverse transcription PCR. Each step in the pipeline maximizes sensitivity and specificity. During the UH2 portion of this application, we propose to conduct the final set of experiments necessary to “lock-down” the analytic process, establish a normal range of these miRNAs by which to quantify the degree of elevation of the miRNAS in cases, demonstrate that this technology is transferrable and that concordant results can be obtained across laboratories, and make final recommendations going into the UH3 portion of the grant on cutpoints for sensitivity and specificity. In the UH3 portion of the application, the serum miRNA test will be prospectively evaluated in the context of an ongoing clinical trial, AGCT1531, that is currently accruing pediatric and adult patients in the United States and Canada and will be opening in the United Kingdom in 2019. The prevalence of the elevated serum miRNAs will be determined in the immediate post-op period and at relapse, and a prospective assessment of the sensitivity, specificity, negative and positive predictive value of the test will be undertaken. With the values gathered prospectively during this clinical trial, the optimal cutpoints for sensitivity and specificity will be recommended, using receiver operating curve methodology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$1 )
2023	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02215	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	11/15/2022	NON-COMPETING CONTINUATION	-$1
														Subtotal = -$1

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	4/14/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	1/21/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $223,649 )
2020	2020	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	2	8/12/2020	NON-COMPETING CONTINUATION	$223,649
														Subtotal = $223,649

Issue Date FY: 2019 ( Subtotal = $215,895 )
2019	2019	DANA-FARBER CANCER INSTITUTE, INC.	450 BROOKLINE AVE	BOSTON	MA	02115	SUFFOLK	USA	Cancer Detection and Diagnosis Research	000	1	9/2/2019	NEW	$215,895
														Subtotal = $215,895

Grand Total All Awards = $439,543

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Assay Validation of a Circulating miRNA Test for Diagnosis and Monitoring of Malignant Germ Cell Tumors

Award Number: UH2CA240688

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/02/2019

PERIOD OF PERFORMANCE END DATE: 04/30/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer